For the latest COVID information Click Here.
Updated November 2020
Golimumab belongs to a class of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). Specifically, it is a TNF inhibitor.
bDMARDs have now been given to over a million people worldwide since their first use in the late 1990s.
These medicines block substances, produced by arthritic tissues, called cytokines. These cytokines are found in excessive amounts in the blood and joints of people with rheumatoid arthritis, psoriatic arthritis, juvenile arthritis and ankylosing spondylitis.
They cause inflammation, which results in symptoms of pain, joint swelling and stiffness, and can lead to joint damage.
By blocking the cytokine called Tumour Necrosis Factor (TNF), golimumab lessens inflammation, pain symptoms and helps stop further joint damage.
Golimumab may be used with other arthritis medicines including:
Golimumab cannot be used with other bDMARDs.
There are separate information sheets for the medicines mentioned above.
You might experience side effects with your treatment. Contact your rheumatologist if you have any concerns about possible side effects. Many side effects disappear when golimumab treatment is stopped.
Most common possible side effects
Less common or rare possible side effects
Use with other diseases
Worsening may occur of the following conditions:
Use with other medicines
More information is available on Vaccinations in Rhematology and COVID-19 vaccination.
Use with alcohol
Use in pregnancy and when breastfeeding